Plain-English translation of NCT04256018 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for two rare types of skin cancer called mycosis fungoides and Sézary syndrome. The study combines , a medication that helps your immune system fight cancer cells, with low-dose radiation therapy applied to your whole skin. Researchers want to see if using these two treatments together works better than either one alone.
Many patients with these skin cancers have already tried standard treatments but still have active disease or need better options. This combination approach aims to offer people a more effective way to control their cancer and improve their quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an infusion (through an IV) multiple times during your first month, then twice monthly afterward. At the same time, you would receive low-dose radiation therapy to your entire skin surface over 2–3 weeks early in treatment. The study will monitor you closely with blood tests and skin evaluations to see how well the treatment works and what side effects occur. The trial is looking to enroll 30 people total.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Stanford University
Enrollment target
~30 participants
Started
March 2020
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zainab Ahmed
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.